Introduction {#tca12917-sec-0005}
============

Non‐small cell lung cancer (NSCLC) is one of the leading causes of cancer death worldwide.[1](#tca12917-bib-0001){ref-type="ref"} Recent advances in the molecular characterization of NSCLC, together with personalized therapies against NSCLC molecular targets, have improved patient prognosis. Testing for activating mutations and rearrangements in the kinase domain of *EGFR*, *ALK*, and *ROS1* is now recommended as part of the routine evaluation of patients with advanced lung adenocarcinoma.[2](#tca12917-bib-0002){ref-type="ref"}, [3](#tca12917-bib-0003){ref-type="ref"} Recently, immune checkpoint inhibitors against PD‐1 have shown remarkable therapeutic activity in NSCLC:[4](#tca12917-bib-0004){ref-type="ref"}, [5](#tca12917-bib-0005){ref-type="ref"}, [6](#tca12917-bib-0006){ref-type="ref"} for example, pembrolizumab has been approved by the United States Food and Drug Administration (USFDA) for first‐line systemic therapy in advanced NSCLC with a PD‐L1 tumor proportion score (TPS) of \> 50% by PD‐L1 22C3 assay.[7](#tca12917-bib-0007){ref-type="ref"} However, testing of both genotype changes and PD‐L1 biomarker levels in routine practice has raised questions about first‐line treatment options when it comes to a PD‐L1 TPS \> 50% combined with targetable oncogenic driver mutations.[3](#tca12917-bib-0003){ref-type="ref"} Notably, accumulating evidence has revealed a relationship between PD‐L1 expression and the presence of driver mutations in *EGFR*, *ALK*, and *KRAS.* [8](#tca12917-bib-0008){ref-type="ref"}, [9](#tca12917-bib-0009){ref-type="ref"}

ROS1 is a transmembrane tyrosine kinase receptor that shares a significant amino acid homology to the kinase domain of ALK.[10](#tca12917-bib-0010){ref-type="ref"} Previous studies have reported that chromosomal rearrangements involving *ROS1* occur in 1--2% of NSCLC and are clinically associated with a history of never‐smoking, younger age, and adenocarcinoma histologic type.[11](#tca12917-bib-0011){ref-type="ref"}, [12](#tca12917-bib-0012){ref-type="ref"} There has been debate over the prevalence of ROS1 abnormality and its mutual exclusiveness to other mutations. Previous studies using fluorescence in situ hybridization (FISH), next‐generation sequencing, or quantitative PCR (qPCR) have reported that the rearrangements in *ROS1* are generally distinct from and mutually exclusive to *EGFR* and *ALK* mutational status.[13](#tca12917-bib-0013){ref-type="ref"}, [14](#tca12917-bib-0014){ref-type="ref"}, [15](#tca12917-bib-0015){ref-type="ref"} In contrast, other studies using immunohistochemistry (IHC) screening alone, or with FISH, have reported that ROS1‐expressing NSCLCs frequently harbor concomitant oncogenic driver mutations.[16](#tca12917-bib-0016){ref-type="ref"}, [17](#tca12917-bib-0017){ref-type="ref"} The low prevalence of ROS1 aberrations and the diversity in the methods used to detect them are the main reasons for the difficulties in defining the clinicopathologic characteristics of ROS1‐aberrant NSCLCs. For example, recent studies assessing PD‐L1 expression in ROS1‐aberrant cases included no more than three cases and showed no statistical association.[3](#tca12917-bib-0003){ref-type="ref"}, [18](#tca12917-bib-0018){ref-type="ref"} PD‐L1 expression shows limited immunoreactivity in older tissue samples[19](#tca12917-bib-0019){ref-type="ref"} and changes after treatment.[20](#tca12917-bib-0020){ref-type="ref"}, [21](#tca12917-bib-0021){ref-type="ref"} The assessment of PD‐L1 expression in routine clinical practice at the time of the initial pathologic diagnosis, before any antitumor treatment, is the best way to evaluate PD‐L1 expression in ROS1‐rearranged NSCLCs, especially during first line treatment.

Therefore, we aimed to examine PD‐L1 expression using a USFDA‐approved companion diagnostic, the 22C3 pharmDx kit (Agilent/Dako, Santa Clara, CA, USA), in a *ROS1*‐rearranged population, by simultaneously genotyping *EGFR*, *ALK*, and *ROS1* in unselected consecutive patients with NSCLC.

Methods {#tca12917-sec-0006}
=======

Patients {#tca12917-sec-0007}
--------

From 2011, the certified Molecular Pathology Center of the Catholic University of Korea Yeouido St. Mary Hospital, South Korea, has been conducting comprehensive genotyping screening for targeted therapy of patients with NSCLC from 36 hospitals in South Korea. From January 2014, *ROS1* FISH has been integrated into the screening platform: a total of 1110 *ROS1* FISH tests have been performed on samples from multiple institutions and 35 (3.2%) cases with *ROS1* rearrangement were found up to December 2017. A total of 407 patients with NSCLC at the Yeouido St. Mary Hospital who consecutively underwent non‐sequential, simultaneous genotyping for *EGFR*, *ALK*, and *ROS1* using tissue samples from the initial pathologic diagnosis or from the immediate subsequent surgery (no previous antitumor treatment) were selected for this study. The patients' clinical data were retrieved from the electronic medical record system of the Yeouido St. Mary Hospital. NSCLC tumor pathology was classified according to World Health Organization criteria.[22](#tca12917-bib-0022){ref-type="ref"} A never‐smoker was defined as a patient who had never smoked or who had smoked \< 100 cigarettes in their lifetime; pack‐years of smoking were calculated as packs‐day multiplied by the years of smoking. Processing and data analysis were performed on pseudonymized data sets. This study was conducted in accordance with the relevant legislation and approved by the institutional review board of Yeouido St. Mary\'s Hospital (SC18RNSI0037) and complied with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all participants included in the study.

Simultaneous diagnostic platform for genotyping and immunohistochemistry {#tca12917-sec-0008}
------------------------------------------------------------------------

We adhered to guidelines previously described for simultaneous genotypic testing and IHC.[23](#tca12917-bib-0023){ref-type="ref"} The sample with the largest tumor proportion and least stroma in each patient was selected for analysis.[24](#tca12917-bib-0024){ref-type="ref"} Additionally, the sample needed to have \>100 tumor cells for the PD‐L1 test[25](#tca12917-bib-0025){ref-type="ref"} and \> 50 tumors cells for ALK and ROS1 FISH tests.[11](#tca12917-bib-0011){ref-type="ref"}, [26](#tca12917-bib-0026){ref-type="ref"} In a tissue‐sparing manner, we also investigated an IHC panel including thyroid transcription factor 1 (TTF‐1), p63, p40, and cytokeratin 7; mucin staining using Periodic acid‐Schiff stain and Alcian blue for histological confirmation; ALK IHC to confirm the FISH results; and PD‐L1 IHC (using the PD‐L1 IHC 22C3 pharmDx, Agilent/Dako) for therapeutic purposes.[23](#tca12917-bib-0023){ref-type="ref"}, [27](#tca12917-bib-0027){ref-type="ref"} PD‐L1 IHC was performed on 4 μm thick formalin‐fixed paraffin‐embedded (FFPE) tissue sections using the PD‐L1 clone 22C3 pharmDx kit and Dako Automated Link 48 platform (Agilent/Dako). Immunohistochemical staining for TTF‐1 (clone SP141, Ventana Medical Systems, Tucson, AZ, USA), p63 (clone 4A4), p40 (polyclonal anti p40; Diagnostic BioSystems, Pleasanton, CA, USA), cytokeratin 7 (clone SP52, Ventana), and ALK (clone 5A4, dilution 1:50, Leica Biosystems, Newcastle, UK) was performed using the Benchmark Ultra Autostainer (Roche Tissue Diagnostics, Tucson, AZ, USA) with an OptiView Universal DAB detection kit for ALK IHC and UltraView universal DAB detection kit for the other proteins (Ventana Medical Systems).

Detection of *EGFR* mutations {#tca12917-sec-0009}
-----------------------------

DNA was isolated from three 5 μm thick FFPE tissue sections using the High Pure PCR Template Preparation Kit (Roche Applied Science, Mannheim, Germany) according to the manufacturer\'s instructions.[23](#tca12917-bib-0023){ref-type="ref"} The extracted DNA was stored at −20 °C until analysis. The PNAClamp EGFR Mutation Detection Kit (PANAGENE Inc., Daejeon, Korea) was used to detect mutations by qPCR, as previously described.[28](#tca12917-bib-0028){ref-type="ref"} Briefly, qPCR was performed in total volume of 20 μL that included template DNA, a primer and peptide nucleic acid (PNA) probe set, and a SYBR Green PCR master mix. The control qPCR lacked the PNA probe and contained the wild‐type (WT) template. The qPCR was performed using a CFX96 PCR detection system (Bio‐Rad, Philadelphia, PA, USA). PCR cycling conditions were as follows: five minutes at 94°C and 40 cycles of 94°C for 30 seconds, 70°C for 20 seconds, 63°C for 30 seconds, and 72°C for 30 seconds. We used the ΔCt method to quantify the amplification: for this purpose, we used threshold cycle (Ct) values, which were automatically calculated from the PCR amplification plots of fluorescence against the number of cycles. ΔCt values were calculated as the Ct value of the standard minus the Ct value of the sample. Higher ΔCt values indicate more efficient amplification of the mutant. A cutoff value of 2.0 was used to indicate the presence of mutant DNA.

*ALK* and *ROS1* rearrangements {#tca12917-sec-0010}
-------------------------------

*ALK* and *ROS1* rearrangements were detected using FISH without prior screening by IHC. FISH is the preferred method used to investigate *ALK* and *ROS1* mutations and is a prerequisite for crizotinib treatment.[29](#tca12917-bib-0029){ref-type="ref"}, [30](#tca12917-bib-0030){ref-type="ref"} Additionally, FISH allows the co‐detection of *ALK* and *ROS1* rearrangements as opposed to sequential staining in IHC. Briefly, FISH was performed on unstained 4 mm thick FFPE tumor samples using the Vysis ALK FISH Break Apart kit and Vysis ROS1 FISH Break Apart kit (Abbott Molecular, Abbot Park, IL, USA), following the manufacturer\'s instructions.[31](#tca12917-bib-0031){ref-type="ref"} FISH images were captured using the automated BioView Duet scanning system (BioView, Rehovot, Israel) and scored by either one or two experienced pathologists. The procedure consisted of the following steps: (i) proper tumor tissue sections were selected for automated imaging and analysis using a 10× objective to locate the nuclei; (ii) the system automatically captured and analyzed the nuclei found in those regions using a 60× oil immersion objective and a single band 4′,6‐diamidino‐2‐phenylindole (DAPI)/Spectrum Green/Spectrum Orange filter; and (iii) the target nuclei were selected and scored by a pathologist using a specific algorithm for positive or negative signal patterns based upon the classifications described in the Vysis ALK FISH Break Apart kit instructions.

A minimum of 50 tumor cell nuclei was counted according to the manufacturer\'s instructions. *ALK* and *ROS1* FISH‐positive cases were defined as those with \> 25 nuclei (50%) with break‐apart (BA) signals or isolated red signals (IRS) for *ALK* and isolated green signals (IGS) for *ROS1. ALK* and *ROS1* FISH‐negative samples were defined as those with \< 5 nuclei (\< 10%) with BA signals or IRS (for *ALK*) and IGS (for *ROS1*). *ALK* and *ROS1* FISH cases were considered borderline if 5--25 cells (10--50%) were positive. In the case of borderline results, a second reader evaluated the slide: 50 additional tumor cell nuclei were counted, and a percentage was calculated from a total of 100 cells. If \< 15% of the cells were positive, the sample was considered negative. If ≥ 15% of the cells were positive, the sample was considered positive.[26](#tca12917-bib-0026){ref-type="ref"}

PD‐L1 tumor proportion score analysis {#tca12917-sec-0011}
-------------------------------------

An experienced pathologist interpreted the expression of PD‐L1. PD‐L1 protein expression was determined by using the TPS, which is the percentage of viable tumor cells showing partial or complete membranous staining at any intensity. The specimen was considered to be negative or positive for PD‐L1 expression at TPS \< 1% and TPS \> 1%, respectively. PD‐L1 expression was subclassified as low PD‐L1 expression with TPS ≥ 1% and TPS \< 50% and high PD‐L1 expression with TPS ≥ 50%.

Statistical analysis {#tca12917-sec-0012}
--------------------

Statistically significant differences between groups were analyzed using the Fisher\'s exact test. Data are expressed as means ± standard deviations. A two‐tailed *P* value \< 0.05 was considered statistically significant. All statistical analyses were performed using R software, version 3.4.1 (R Foundation, Vienna, Austria).

Results {#tca12917-sec-0013}
=======

Baseline clinical and pathologic characteristics of patients {#tca12917-sec-0014}
------------------------------------------------------------

Among the 407 patients with NSCLC, 238 (58.6%) were male, and the mean patient age was 66.9 years (Table [1](#tca12917-tbl-0001){ref-type="table"}). The predominant histologic type was adenocarcinoma (306 cases, 75.4%), and 183 (46.4%) patients were never‐smokers. A high percentage of the study population (56.6%) had advanced stage cancer (stages IIIB and IV). Stage information was not available for 12 patients. Most of the study specimens (96.1%) were obtained by non‐surgical biopsy (bronchoscopic biopsy, 10.3%; percutaneous needle aspiration biopsy, 73.4%; metastatic site biopsy, 8.7%; cell block from pleural effusion, 1.2%; and endobronchial ultrasound‐guided transbronchial needle aspiration, 2.5%); the remainder was obtained by surgical resection (lobectomy, 3.2%; wedge resection, 0.7%).

###### 

Demographics of *EGFR*, *ALK*, and *ROS1* status in 407 NSCLC consecutive patients

                                       *EGFR* (*n* = 106)  *ALK* (*n* = 19)                                       *ROS1* (*n* = 14)                                                                        
  -------------------- -------------- -------------------- ------------------------------------------------------ ------------------- ------------------------------------------------------ ------------- ------------------------------------------------------
  Age, mean ± SD       66.9 ± 12.07       64.8 ± 12.0      **0.033** [‡](#tca12917-note-0002){ref-type="fn"}      55.7 ± 15.7          **\< 0.001** [†](#tca12917-note-0001){ref-type="fn"}  61.2 ± 15.5    **\< 0.001** [†](#tca12917-note-0001){ref-type="fn"}
  Gender, N (%)                                                                                                                                                                                            
  Male                 238 (58.6)          29 (27.4)       **\< 0.001**                                           7 (36.8)                                    0.058                          4 (28.6)                            **0.026**
  Female               168 (41.4)          77 (72.6)       12 (63.2)                                              10 (71.4)                                                                                
  Smoking history                                                                                                                                                                                          
  Never smoker         183 (46.4)          76 (73.8)       **\< 0.001**                                           14 (73.7)                                 **0.018**                        10 (71.4)                             0.098
  Ever smoker          211 (53.6)          27 (26.2)       5 (26.3)                                               4 (28.6)                                                                                 
  Packyears            19.5 ± 23.6         5.5 ± 11.6      **\< 0.001** [‡](#tca12917-note-0002){ref-type="fn"}   6.9 ± 14.8            **0.001** [‡](#tca12917-note-0002){ref-type="fn"}    12.1 ± 24.3        0.237[‡](#tca12917-note-0002){ref-type="fn"}
  Histology                                                                                                                                                                                                
  ADC                  306 (75.4)          101 (95.3)      **\< 0.001** [§](#tca12917-note-0003){ref-type="fn"}   17 (89.5)                                  0.179 §                         14 (100)        **0.026** [§](#tca12917-note-0003){ref-type="fn"}
  SCC                  74 (18.2)            4 (3.8)        1 (5.3)                                                0 (0.0)                                                                                  
  ADSQ                 9 (2.2)              1 (0.9)        0 (0.0)                                                0 (0.0)                                                                                  
  Other NSCLCs         17 (4.2)             0 (0.0)        1 (5.3)                                                0 (0.0)                                                                                  
  Stage                                                                                                                                                                                                    
  IA                   60 (15.2)           20 (19.6)       **\< 0.001** [¶](#tca12917-note-0004){ref-type="fn"}   2 (10.5)              **0.006** [¶](#tca12917-note-0004){ref-type="fn"}    1 (7.1)         **0.001** [¶](#tca12917-note-0004){ref-type="fn"}
  IB                   37 (9.4)             10 (9.8)       0 (0.0)                                                1 (7.1)                                                                                  
  IIA                  18 (4.6)             7 (6.9)        1 (5.3)                                                0 (0.0)                                                                                  
  IIB                  18 (4.6)             2 (2.0)        1 (5.3)                                                1 (7.1)                                                                                  
  IIIA                 38 (9.6)             7 (6.9)        2 (10.5)                                               0 (0.0)                                                                                  
  IIIB                 32 (8.1)             6 (5.9)        0 (0.)                                                 0 (0.0)                                                                                  
  IV                   191 (48.5)          50 (49.0)       13 (68.4)                                              11 (78.6)                                                                                
  Type of sample                                                                                                                                                                                           
  Biopsy                                                   0.258[††](#tca12917-note-0005){ref-type="fn"}                                  1.000[††](#tca12917-note-0005){ref-type="fn"}                        1.000[††](#tca12917-note-0005){ref-type="fn"}
  Bronchoscopy         42 (10.3)            6 (5.7)        3 (15.8)                                               1 (7.1)                                                                                  
  PCNB                 298 (73.4)          87 (82.1)       13 (68.4)                                              9 (64.3)                                                                                 
  Metastatic site      35 (8.7)             7 (6.6)        3 (15.8)                                               3 (21.4)                                                                                 
  Cell block           5 (1.2)              3 (2.8)        0 (0.0)                                                1 (7.1)                                                                                  
  EBUS‐TBNA            10 (2.5)             1 (0.9)        0 (0.0)                                                0 (0.0)                                                                                  
  Surgical resection                                                                                                                                                                                       
  Lobectomy            13 (3.2)             2 (1.9)        0 (0.0)                                                0 (0.0)                                                                                  
  Wedge resection      3 (0.7)              0 (0.0)        0 (0.0)                                                0 (0.0)                                                                                  

*P* value was evaluated compared to wild type for the gene.

Evaluated by *t*‐test.

Adenocarcinoma versus all others.

Stage I--IIIa versus IIIb--IV.

Biopsy versus surgical resection.

Values in bold are statistically significant.

ADC, adenocarcinoma; SCC, squamous cell carcinoma; ADSQ, adeno‐squamous carcinoma; NSCLC, non‐small cell lung cancer; PCNB, percutaneous needle aspiration biopsy; EBUS‐TBNA, endobronchial ultrasound‐transbronchial needle aspiration biopsy.

Genetic alterations of *EGFR*, *ALK*, and *ROS1* {#tca12917-sec-0015}
------------------------------------------------

As shown in Table [1](#tca12917-tbl-0001){ref-type="table"}, among the 407 patients, we identified 106 (26.0%) *EGFR* mutations, and 19 (4.7%) *ALK* and 14 (3.4%) *ROS1* rearrangements. Among the squamous cell carcinoma cases, none had a *ROS1* rearrangement, one had an *ALK* mutation, and four had an *EGFR* mutation. In this cohort, coexisting genetic alterations were detected in two patients (0.7%): one had an *EGFR* mutation with an *ALK* rearrangement, the other had an *EGFR* mutation with a *ROS1* rearrangement.

When comparing patients with WT or mutated oncogenes, we found that younger age and advanced stage (IIIB and IV) were significantly associated with the three oncogene mutations. *EGFR* mutations were significantly more frequent in patients with the following characteristics: younger age (*P* = 0.033), female gender (*P* \< 0.001), never‐smoker (*P* \< 0.001), shorter smoking timeframe (pack‐years, *P* \< 0.001), adenocarcinoma (*P* \< 0.001), and advanced stage (IIIB and IV; *P* \< 0.001). A similar pattern was observed in patients with *ALK* and *ROS1* rearrangements. Specifically, younger age (*P* \< 0.001), never‐smoker (*P* = 0.018), shorter smoking timeframe (*P* \< 0.001), and advanced tumor stage (*P* = 0.006) were also significantly associated with *ALK* rearrangements, while *ROS1* rearrangements were significantly associated with younger age (*P* \< 0.001), female gender (*P* = 0.026), adenocarcinoma (*P* = 0.026), and advanced tumor stage (*P* \< 0.001).

Association of *EGFR*, *ALK*, and *ROS1* gene mutation with PD‐L1 expression {#tca12917-sec-0016}
----------------------------------------------------------------------------

Table [2](#tca12917-tbl-0002){ref-type="table"} shows the relationship between *EGFR, ALK,* and *ROS1* gene mutations and PD‐L1 expression. From September 2016 onwards, the PD‐L1 22C3 test was performed on 130 consecutive patients with NSCLC; we identified 29 cases (22.3%) with high PD‐L1 expression, 59 cases (45.4%) with low PD‐L1 expression, and 42 cases (32.3%) with no PD‐L1 expression. *EGFR* WT status was significantly associated with PD‐L1 expression (TPS \> 1%, *P* = 0.031). *ALK* rearrangement showed no association with PD‐L1 expression, while *ROS1* rearrangement was significantly associated with high PD‐L1 expression (*P* = 0.031).

###### 

Oncogenic aberration and PD‐L1 expression in 130 consecutive NSCLC patients

  ------------------------------------------------------------------------------------------------------------------
                     PD‐L1 expression                           
  ------------------ ------------------ ----------- ----------- ----------------------------------------------------
  *EGFR*, N (%)                                                 

  Negative           26 (61.9)          45 (76.3)   26 (89.7)      0.051[‡](#tca12917-note-0009){ref-type="fn"}\
                                                                 **0.031** [§](#tca12917-note-0010){ref-type="fn"}

  Positive           16 (38.1)          14 (23.7)   3 (10.3)    

  Exon 19 deletion   5 (11.9)           6 (9.0)     2 (10.5)    

  Exon 21 L858R      7 (16.7)           4 (2.6)     0 (0.0)     

  Others             4 (9.5)            4 (0.7)     1 (5.3)     

  *ALK*, N (%)                                                  

  Negative           41 (97.6)          55 (93.2)   27 (93.1)      0.652[‡](#tca12917-note-0009){ref-type="fn"}\
                                                                    0.427[§](#tca12917-note-0010){ref-type="fn"}

  Positive           1 (2.4)            4 (6.8)     2 (6.9)     

  *ROS1*, N (%)                                                 

  Negative           42 (100.0)         58 (98.3)   26 (89.7)    **0.031** [‡](#tca12917-note-0009){ref-type="fn"}\
                                                                    0.304[§](#tca12917-note-0010){ref-type="fn"}

  Positive           0 (0.0)            1 (1.7)     3 (10.3)    
  ------------------------------------------------------------------------------------------------------------------

*P* was evaluated by comparison with the wild type gene.

PD‐L1 \< 50% versus PD‐L1 ≥ 50%.

PD‐L1 \< 1% versus PD‐L1 ≥ 1%.

Values in bold are statistically significant.

Clinicopathologic profiles of patients with *ROS1* gene mutations {#tca12917-sec-0017}
-----------------------------------------------------------------

The characteristics of the patients with *ROS1* rearrangements are shown in Table [3](#tca12917-tbl-0003){ref-type="table"} and Figure [1](#tca12917-fig-0001){ref-type="fig"}. Most of the patients were female (71.4%), never‐smokers (71.4%), at advanced tumor stage (IV, 78.6%). All patients had adenocarcinoma. Two coexisting mutations (*EGFR* and *ROS1* mutations) were detected in one patient. Because of the unexpectedly strong association between high PD‐L1 expression and *ROS1* mutation in four *ROS1*‐rearranged cases, we additionally performed PD‐L1 assay on the 10 earlier cases with *ROS1* rearrangement that had not been tested for PD‐L1 expression. Out of the 14 *ROS1* mutated patients, five (35.7%) had high PD‐L1 expression, 7 (50.0%) had low PD‐L1 expression, and 2 (14.2%) were negative for PD‐L1 expression.

###### 

Clinicopathologic profiles of patients with *ROS1* rearrangement

  Patient   Age   Gender    Smoking  Pack‐years   Cell type        Sample             Stage      *EGFR*      *ALK*      PD‐L1 (%)   *ROS1* (%)
  --------- ----- -------- --------- ------------ ---------------- ----------------- ------- --------------- ---------- ----------- ------------
  1         66    Male         Y     50           Adenocarcinoma   Bronchoscopy        IV         *WT*       Negative   10          28
  37        79    Female       N     0            Adenocarcinoma   Cell block          IV         *WT*       Negative   80          54
  46        59    Female       N     0            Adenocarcinoma   PCNB                IV         *WT*       Negative   5           29
  70        76    Male         Y     75           Adenocarcinoma   Metastatic site     IV         *WT*       Negative   0           59
  275       72    Male         Y     40           Adenocarcinoma   PCNB                IB         *WT*       Negative   30          58
  276       79    Female       N     0            Adenocarcinoma   PCNB                IV         *WT*       Negative   95          27
  282       43    Female       N     0            Adenocarcinoma   PCNB                IA         *WT*       Negative   25          88
  300       80    Female       N     0            Adenocarcinoma   PCNB                IV     Exon 21 L858R  Negative   25          49
  360       69    Female       N     0            Adenocarcinoma   PCNB                IV         *WT*       Negative   2           31
  375       57    Female       N     0            Adenocarcinoma   PCNB                IV         *WT*       Negative   0           86
  396       47    Female       N     0            Adenocarcinoma   PCNB                IIB        *WT*       Negative   1           62
  404       44    Female       N     0            Adenocarcinoma   Metastatic site     IV         *WT*       Negative   66          88
  406       33    Male         Y     5            Adenocarcinoma   Metastatic site     IV         *WT*       Negative   90          62
  407       53    Female       N     0            Adenocarcinoma   PCNB                IV         *WT*       Negative   88          86

WT, wild type; PCNB, percutaneous needle aspiration biopsy.

![PD‐L1 tumor proportion score (TPS) in several cases of adenocarcinoma with positive fluorescence in situ hybridization (FISH) ROS1 split signal. (**a**) Case no. 407 showed adenocarcinoma histology (left panel), positive *ROS1* FISH, mainly break‐apart signal (middle panel), and high PD‐L1 expression (right panel). (**b**) Case no. 404 showed adenocarcinoma histology (left panel), positive *ROS1* FISH, mainly isolated green signal (middle panel) and high PD‐L1 expression (right panel). (**c**) Case no. 282 showed adenocarcinoma histology (left panel), positive *ROS1* FISH, mainly break‐apart signal (middle panel), and low PD‐L1 expression (right panel). (**d**) Case no. 396 showed adenocarcinoma histology (left panel), positive *ROS1* FISH, mainly isolated green signal (middle panel), and low PD‐L1 expression (right panel).](TCA-10-103-g001){#tca12917-fig-0001}

Discussion {#tca12917-sec-0018}
==========

To the best of our knowledge, our study is the first to simultaneously diagnose genetic alterations in *EGFR*, *ALK*, and *ROS1* in an unselected Asian population. Previous studies have reported that the frequency of *ROS1* rearrangement in *EGFR*/*KRAS*/*ALK* WT and never‐smoking patients with lung adenocarcinoma is 5.7--8.3%.[32](#tca12917-bib-0032){ref-type="ref"}, [33](#tca12917-bib-0033){ref-type="ref"} In an unselected NSCLC population, the rate of *ROS1* mutation is 0.6--4.5%.[11](#tca12917-bib-0011){ref-type="ref"}, [14](#tca12917-bib-0014){ref-type="ref"}, [34](#tca12917-bib-0034){ref-type="ref"}, [35](#tca12917-bib-0035){ref-type="ref"}, [36](#tca12917-bib-0036){ref-type="ref"} Consistently, in this study, the rate of *ROS1* rearrangement was 3.4% (14/407).

There were no cases of co‐occurring *ROS1* and *ALK* mutation, but one case of co‐occurring *ROS1* and *EGFR* mutation was found. These findings are similar to those of previous studies suggesting that *ROS1* rearrangements are mutually exclusive to other oncogenic changes.[11](#tca12917-bib-0011){ref-type="ref"}, [14](#tca12917-bib-0014){ref-type="ref"}, [36](#tca12917-bib-0036){ref-type="ref"}, [37](#tca12917-bib-0037){ref-type="ref"} However, others have reported that *ROS1* rearrangements occur in conjunction with other driver mutations.[16](#tca12917-bib-0016){ref-type="ref"}, [17](#tca12917-bib-0017){ref-type="ref"} This inconsistency may be a result of differences in *ROS1* testing techniques. Updated molecular testing guidelines recommend that, while ROS1 IHC may be used as a screening test, any finding should be confirmed by molecular (qPCR) or cytogenetic (FISH) testing.[2](#tca12917-bib-0002){ref-type="ref"} Wiesweg *et al*. reported that 36% of *ROS1* IHC‐positive cases have a concomitant *EGFR* mutation; however, only about half of the cases showed *ROS1* rearrangement by FISH.[17](#tca12917-bib-0017){ref-type="ref"} This result suggests that IHC results include a high number of false‐positives. The significance of ROS1 IHC differs from that of ALK IHC: ALK expression is highly specific to tumors with *ALK* rearrangement,[31](#tca12917-bib-0031){ref-type="ref"} whereas ROS1 is expressed at typically low and occasionally high levels in tumors lacking *ROS1* rearrangement.[15](#tca12917-bib-0015){ref-type="ref"}, [38](#tca12917-bib-0038){ref-type="ref"}, [39](#tca12917-bib-0039){ref-type="ref"} Therefore, we chose *ROS1* FISH testing as the initial screening test.

In this study, *ROS1*‐rearranged NSCLCs were exclusively adenocarcinomas and were predominantly observed in women and younger patients, in line with previous studies.[11](#tca12917-bib-0011){ref-type="ref"}, [14](#tca12917-bib-0014){ref-type="ref"}, [36](#tca12917-bib-0036){ref-type="ref"}, [40](#tca12917-bib-0040){ref-type="ref"}

As a result of the use of pembrolizumab in first‐line therapy, its companion diagnostic PD‐L1 22C3 assay has become a major tool in the routine clinical testing of NSCLC.[3](#tca12917-bib-0003){ref-type="ref"} Increasing costs and medical complexity are significant challenges in organizing the diagnostic platform of biomarkers in NSCLCs, especially in relation to the prevalence and mutual exclusiveness of these biomarkers.[41](#tca12917-bib-0041){ref-type="ref"}, [42](#tca12917-bib-0042){ref-type="ref"}, [43](#tca12917-bib-0043){ref-type="ref"} Accumulating evidence has revealed a relationship between PD‐L1 expression and driver mutations. Previous studies have shown that activating *EGFR* mutations induce PD‐L1 expression in cell lines and animal models.[8](#tca12917-bib-0008){ref-type="ref"}, [44](#tca12917-bib-0044){ref-type="ref"} Moreover, some studies have shown more frequent PD‐L1 expression in NSCLC with *EGFR* mutations.[8](#tca12917-bib-0008){ref-type="ref"}, [45](#tca12917-bib-0045){ref-type="ref"} These observations support the theory of an immunologic evasion mechanism by *EGFR*‐mutated lung cancer and suggest that therapeutic blockade of the PD‐1/PD‐L1 pathway could improve the treatment of patients with NSCLC carrying an *EGFR* mutation. On the contrary, a previously published study revealed the lack of high PD‐L1 expression in *EGFR*, *ALK*, or *ROS1‐*mutated lung adenocarcinoma and proposed therapeutic subgrouping as *EGFR/ALK/ROS1* affected, high PD‐L1 expressing, and biomarker negative groups.[3](#tca12917-bib-0003){ref-type="ref"} Another large meta‐analysis reported that PD‐L1 expression is associated with gender, smoking status, histology, and tumor size; *EGFR* WT status was associated with PD‐L1 expression, while *ALK* or *KRAS* mutations were not.[8](#tca12917-bib-0008){ref-type="ref"} These data are consistent with the correlation between PD‐L1 expression and *EGFR* WT status we found. PD‐L1 expression in *ROS1*‐rearranged NSCLC has not been assessed prior to our study. Interestingly, 5 (35.7%) of the 14 patients with *ROS1* rearrangement had high PD‐L1expression, and high PD‐L1 expression was also significantly associated with *ROS1* rearrangement in our consecutive cohort, which is the largest PD‐L1 study cohort so far. Based on our results, *ROS1* rearrangement and high PD‐L1 expression (≥ 50%) are not mutually exclusive but correlate. Further studies are necessary to establish the exact relationship between PD‐L1 expression and *ROS1* rearrangement.

There are some limitations to this study. First, we have no data on the immune checkpoint inhibitor treatment response in patients with oncogenic driver mutations because our national insurance only covers pembrolizumab as a second‐line NSCLC treatment, while it covers other tyrosine kinase inhibitors as first‐line treatment. Second, PD‐L1 expression was only tested in 130 consecutive patients and the PD‐L1 test in *ROS1* rearrangement cases was partly performed on a simultaneous platform because PD‐L1 has been only recently integrated into the routine diagnostic platform. Third, the number of *ROS1* rearrangements was small even though this was the largest cohort analyzed so far. Thus, further research is needed to generalize our findings. Despite these limitations, this study is a large‐scale screen using simultaneous panel genotyping of *EGFR, ALK*, and *ROS1* in unselected patients, which show mutual exclusiveness with other targetable mutations and demonstrates a strong association between *ROS1* rearrangement and high PD‐L1 expression.
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